TICKERNERD
Menu
PRCTPRCTHealthcare · Medical Devices

PRCT Stock Forecast: PROCEPT BioRobotics Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$22
+4.58% on the day

The 14 Wall Street analysts covering PROCEPT BioRobotics Corp. hold a median 12-month price target of $21 — -3.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$1.2B
Ticker Nerd rank
38 / 100
Median analyst target
$21
Analysts covering
14
Total return, dividends reinvested
1W
+0.1%
1M
+17.1%
YTD
−31.1%
1Y
−44.9%
From 52W high
−47.4%
From 52W low
+29.9%
$17
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PROCEPT BioRobotics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
72
Quality
71
Accruals
60
Issuance
52
Value
50
Size
43
Revisions
42
Growth
37
Momentum
11

Volatility (72): The share price has been relatively steady.

Momentum (11): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PRCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26PRCTHigh $28Median $21Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
4 Buy9 Hold1 Sell
Low $16Median $21High $28

The green dot is the last close — the median target sits −3.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
5 Aug 2026Evercore ISI GroupMaintainsOutperform$30 → $23
5 Aug 2026Piper SandlerMaintainsOverweight$35 → $25
5 Aug 2026TD CowenMaintainsBuy$34 → $28
5 Aug 2026William BlairDowngradeMarket Perform—
28 July 2026UBSAssumesNeutral$20
6 July 2026Truist SecuritiesDowngradeHold—
6 July 2026Truist SecuritiesDowngradeHold$30 → $25
24 June 2026Evercore ISI GroupInitiatesOutperform—
11 June 2026Leerink PartnersDowngradeMarket Perform—
30 Apr 2026Piper SandlerReiteratesOverweight—
6 Mar 2026BairdInitiatesNeutral—
2 Mar 2026Truist SecuritiesMaintainsBuy—
26 Feb 2026B of A SecuritiesDowngradeUnderperform—
26 Feb 2026Leerink PartnersMaintainsOutperform—
26 Feb 2026OppenheimerDowngradePerform—
26 Feb 2026Piper SandlerMaintainsOverweight—
26 Feb 2026TD CowenMaintainsBuy—
26 Feb 2026Wells FargoMaintainsOverweight—
18 Dec 2025Truist SecuritiesMaintainsBuy—
12 Dec 2025UBSInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PRCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
8
Fundamentals

PROCEPT BioRobotics Corp. (PRCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.1×

Cheaper than 94% of US stocks

Price / sales
3.5×

Cheaper than 36% of US stocks

Price / book
3.5×

Cheaper than 30% of US stocks

EV / EBITDA
−10.3×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
19.3%

Higher than 69% of US stocks

Earnings growth (YoY)
19.3%

Higher than 58% of US stocks

Gross margin
66.0%

Higher than 80% of US stocks

Operating margin
−29.0%

Higher than 20% of US stocks

Net margin
−32.5%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−30.2%

Higher than 27% of US stocks

Return on assets
−14.4%

Higher than 23% of US stocks

Dividend yield
2.3%

Higher than 52% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PRCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PRCTPROCEPT BioRobotics Corp.$1.2B
38
BVSBioventus, Inc.$1.2B
98
LMRILumexa Imaging Holdings, Inc.$1.2B
2
IARTIntegra LifeSciences Holdings Corp.$1.3B
89
IRMDIRadimed Corp.$1.1B
92
AORTArtivion, Inc.$1.4B
45
ATECAlphatec Holdings, Inc.$1.4B
76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PROCEPT BioRobotics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRCT news & analysis

PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit

PRNewsWire · 21 Aug 2026negative

Rosen Law Firm reminded purchasers of PROCEPT BioRobotics Corporation (PRCT) common stock between February 28, 2024 and February 25, 2026 of the September 22, 2026 lead plaintiff deadline in a securities fraud lawsuit. Investors who bought during the Class Period may be entitled to compensation through a contingency fee arrangement.

Why it matters — PRCT watchers would note the pending securities fraud litigation and its lead plaintiff deadline, which could affect the company's legal and financial outlook.

PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with SBS Law

GlobeNewsWire · 21 Aug 2026negative

SBS Law, a shareholder rights firm, reminded investors about a securities fraud class action lawsuit against PROCEPT BioRobotics alleging violations of the Securities Exchange Act of 1934. Shareholders who purchased PRCT stock during the defined class period are encouraged to contact the firm regarding lead plaintiff appointments.

Why it matters — The securities fraud lawsuit against the company signals potential legal and reputational risk for PRCT that shareholders may want to monitor.

PROCEPT BioRobotics Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRCT

PRNewsWire · 21 Aug 2026negative

The DJS Law Group has reminded investors of a class action lawsuit against PROCEPT BioRobotics Corporation alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Shareholders who purchased PRCT shares during the specified class period are encouraged to contact the firm regarding possible lead plaintiff appointments.

Why it matters — PRCT shareholders face legal uncertainty from a securities class action, and those who purchased during the class period may need to consider their rights as potential lead plaintiffs.

FAQ

Frequently asked questions about PRCT stock

What is the PRCT stock price forecast for 2026-2027?

The 14 Wall Street analysts covering PROCEPT BioRobotics Corp. have a median 12-month price target of $21, with estimates ranging from $16 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRCT stock a buy right now?

Of the 14 analysts covering PROCEPT BioRobotics Corp., 4 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PROCEPT BioRobotics Corp. 38 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRCT?

As at 22 Aug 2026, PROCEPT BioRobotics Corp. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (72 of 100).

Will PRCT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies -3.1% from the last close, and Ticker Nerd's factor model ranks PROCEPT BioRobotics Corp. 38 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRCT stock forecast for 2030?

No analyst covering PROCEPT BioRobotics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $28 over the next 12 months.

How has PRCT stock performed over the past year?

PROCEPT BioRobotics Corp. returned -44.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PROCEPT BioRobotics Corp. do?

PROCEPT BioRobotics Corporation is a medical technology company focused on robotic solutions for urology. PROCEPT BioRobotics Corporation develops, manufactures, and sells image-guided surgical systems used in minimally invasive procedures for benign prostatic hyperplasia, or BPH, a common condition that affects urinary flow in men.

What is the latest news on PRCT?

The most recent item we track (PRNewsWire, 21 Aug 2026): "PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit". Rosen Law Firm reminded purchasers of PROCEPT BioRobotics Corporation (PRCT) common stock between February 28, 2024 and February 25, 2026 of the September 22, 2026 lead plaintiff deadline in a securities fraud lawsuit. Investors who bought during the Class Period may be entitled to compensation through a contingency fee arrangement.

Company

About PROCEPT BioRobotics Corp.

PROCEPT BioRobotics Corporation is a medical technology company focused on robotic solutions for urology. PROCEPT BioRobotics Corporation develops, manufactures, and sells image-guided surgical systems used in minimally invasive procedures for benign prostatic hyperplasia, or BPH, a common condition that affects urinary flow in men. Its product portfolio centers on the AQUABEAM Robotic System and the HYDROS Robotic System, which support Aquablation therapy by combining robotics, imaging, and controlled waterjet-based tissue removal. The company also provides associated instruments, consumables, and service support, creating a recurring business model tied to procedure adoption and installed systems. PROCEPT BioRobotics Corporation serves hospitals and urology specialists in the United States and selected international markets, positioning itself as a specialized player in robotic surgical care for prostate treatment.

CEO Mr. Larry L. Wood · 888 employees · United States · https://www.procept-biorobotics.com